TG Therapeutics, Inc.
TGTX
$28.74
$0.782.79%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 192.57M | 161.71M | 141.15M | 120.86M | 108.19M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 192.57M | 161.71M | 141.15M | 120.86M | 108.19M |
| Cost of Revenue | 38.14M | 28.09M | 18.94M | 15.54M | 15.40M |
| Gross Profit | 154.43M | 133.62M | 122.21M | 105.32M | 92.79M |
| SG&A Expenses | 62.75M | 63.37M | 55.59M | 50.33M | 38.96M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 142.08M | 132.34M | 106.31M | 112.23M | 78.24M |
| Operating Income | 50.49M | 29.37M | 34.84M | 8.62M | 29.95M |
| Income Before Tax | 45.09M | 25.91M | 30.92M | 5.47M | 25.45M |
| Income Tax Expenses | 22.06M | -364.99M | 2.73M | 408.00K | 2.12M |
| Earnings from Continuing Operations | 23.04M | 390.90M | 28.19M | 5.06M | 23.33M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 23.04M | 390.90M | 28.19M | 5.06M | 23.33M |
| EBIT | 50.49M | 29.37M | 34.84M | 8.62M | 29.95M |
| EBITDA | 50.52M | 29.38M | 34.86M | 8.63M | 29.96M |
| EPS Basic | 0.16 | 2.69 | 0.19 | 0.03 | 0.16 |
| Normalized Basic EPS | 0.20 | 0.11 | 0.13 | 0.02 | 0.11 |
| EPS Diluted | 0.14 | 2.43 | 0.17 | 0.03 | 0.15 |
| Normalized Diluted EPS | 0.18 | 0.10 | 0.12 | 0.02 | 0.10 |
| Average Basic Shares Outstanding | 142.96M | 145.42M | 146.74M | 146.68M | 145.24M |
| Average Diluted Shares Outstanding | 159.37M | 161.00M | 162.56M | 162.77M | 160.24M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |